

# HEALTHCARE SECTOR BULLETIN

December 2015

QUADRIA  
CAPITAL

## HEALTHCARE TRENDS & IMPACT STORIES

---

Country: Vietnam  
Headline: **Vietnam needs to improve mental healthcare resources**  
Summary: Vietnam faces several difficulties in mental healthcare due to shortage of medical facilities, and human and financial resources.

Vice-Director of the health ministry's Medical Services Administration Tran Quy Tuong said at a consultative workshop on the National Strategy on Mental Health today in Ha Noi that the country's human resources in mental healthcare was weak, both in terms of quality and quantity, with only 650 doctors working in 63 provinces and cities. Insufficient mental healthcare services and lack of comprehensive legal corridors were also challenges for the development of mental healthcare in Viet Nam, Tuong said.

The Ministry of Health has submitted a plan on national strategy on mental health for the 2016-25 period to the prime minister. Mental health care services will be offered comprehensively and included in the treatment options at general hospitals throughout Vietnam, especially those at the district level, according to the plan.

A survey of the health sector showed that about 15 per cent of Viet Nam's population, or 13 million people, have mental disorders such as schizophrenia, depression, epilepsy and mental disorders after brain injuries.

Link <http://vietnamnews.vn/society/279537/viet-nam-needs-to-improve-mental-healthcare-resources.html>

---

Country: India  
Headline: **Manipal Hospitals Adopts Watson for Oncology to Help Physicians Identify Options for Individualized, Evidence-Based Cancer Care Across India**  
Summary: IBM announced that Manipal Hospitals' corporate and teaching facilities will adopt Watson for Oncology, a cognitive computing platform trained by Memorial Sloan-Kettering that analyzes data to identify evidence-based treatment options, helping oncologists to provide cancer patients with individualized healthcare. More than 200,000 individuals receive care for cancer at Manipal facilities each year. This will be the first deployment of Watson in India and the first engagement of its kind as the country advances efforts to transform healthcare.

"We are at an inflection point in India regarding cancer care, driven by the increasing number of cancer patients in India, fewer oncologists to treat them and the broad geographic footprint of our region. These challenges are amplified by rapid advances in personalized medicine, and an ever-growing amount and diversity of clinical evidence. All these factors compelled us to consider how a technology-based solution could help deliver at scale world class cancer care to our patients," said Dr. Ajay Bakshi, Managing Director & CEO of Manipal Hospitals. "With IBM's Watson for Oncology, we can combine our clinicians' expertise across various types of cancers with a cognitive computing solution informed by expert training from Memorial Sloan Kettering Cancer Center. We believe the result will be to raise the level of care throughout the region."

"This engagement represents a major step in the transformation of healthcare in India. With IBM Watson we are bringing cognitive computing to the healthcare ecosystem to help deliver greater value to patients in India," said Vanitha Narayanan, Managing Director, IBM India.

Link <http://www-03.ibm.com/press/us/en/pressrelease/48189.wss>

## HEALTHCARE SECTOR NOTABLE TRANSACTIONS

---

Country: Philippines

Headline: ***Philippines: MPHH acquires 20% in Manila Medical Services for PHP 708m***

Summary: Metro Pacific Hospital Holdings Inc (MPHH) secured Monday its acquisition of a 20% stake in Manila Medical Services Inc (MMSI) for PHP 708m.

MPHH closed the deal less than two weeks after signing an investment agreement to acquire a 51% shareholding in a provincial hospital, the Sacred Heart Hospital of Malolos Inc (SHHM) in Bulacan, investing in PHP 150m.

MMSI owns Manila Doctors Hospital (MDH) from Metrobank Foundation Inc (MBFI), the controlling shareholder of MMSI.

MPHH, however, is the hospital investment arm of listed firm Metro Pacific Investments Corp.

MDH is now the 10th hospital investment of MPHH.

Links: <http://www.dealstreetasia.com/stories/philippines-mphh-acquires-20-manila-medical-services-708m-25169/>

---

Country: India

Headline: ***India Value Fund picks minority in Cloudnine Hospitals for USD 60m***

Summary: India Value Fund Advisors (IVFA) on Thursday said it has invested INR 4bn for a significant minority stake in Bengaluru-based maternity and infant care chain Cloudnine Hospitals, joining existing investors Matrix Partners India and Sequoia India.

The stake sale was done at an enterprise value of INR 14bn, said Rohit M.A., managing director of Cloudnine. Cloudnine said it plans to use the proceeds of the stake sale to set up 12-15 hospitals in western India, the National Capital Region (NCR) and south India, in addition to investment in technology.

Started in 2007 by renowned neonatologist Kishore Kumar, Cloudnine Hospitals is a joint venture of Kids Clinic India Pvt. Ltd and property developer Scrips N Scrolls India. From a single hospital in south Bangalore, Cloudnine has expanded its operations to 10 hospitals and five clinics across Bangalore, Chennai, Gurgaon, Mumbai and Pune.

“The focus of the partnership and investment will be to further strengthen the core value proposition of the Cloudnine brand and extend the company’s leadership position in the women and child healthcare services segment as the company builds out a pan-India footprint,” said Dhondiyal of IVFA.

Maternity and child care hospital chains have become attractive investment destinations for private equity investors in recent years. With maternity care not considered a disease, people are increasingly opting for boutique maternity and child care hospitals.

Links: <http://www.dealstreetasia.com/stories/ivfa-invests-rs400-crore-in-cloudnine-hospitals-24891/>

## TRANSACTION NEWS

Date	Headlines	Summary
31-Dec	<b>Thyrocare Technologies files draft prospectus for IPO of up to 10,744,708 shares (Source: Company website)</b>	Thyrocare Technologies, the India-based thyroid testing services company, has filed a draft prospectus for an IPO of up to 10,744,708 shares. According to Thyrocare Technologies' draft IPO prospectus, the proposed IPO will be via an "Offer for Sale" by four "Selling Shareholders".
31-Dec	<b>Toshiba Medical interests Sony, GE Healthcare - report (translated) (Source: Nihon Keizai Shimbun)</b>	Sony Corp. [TYO:6758] and General Electric Co.'s [NYSE:GE] GE Healthcare were found among the suitors of Toshiba Medical Systems Corp., Toshiba's fully-owned maker of medical equipment, which is expected to be on sale in January, the Nihon Keizai Shimbun reported. Several investment funds, including KKR, the US-based private equity giant, are also interested in the medical equipment maker and developer, and a joint acquisition by several parties would be possible, the Japanese newspaper report said, without citing sources.
31-Dec	<b>Pharmswellbio 11% stake sold by Service-In and related party to Diorpharm for KRW 16.1bn (Source: Stock Exchange Announcement (Translated))</b>	Service-In, an unlisted Internet content distribution company, announced today that along with a related party, it has sold a combined 10.95% stake in Pharmswellbio (KOSDAQ:043090), the listed medical equipment maker, to Diorpharm. The bidder is an unlisted South Korean cosmetics wholesaler, the stock exchange announcement said. The deal value is KRW 4,253.68 a share for 2,189,777 shares held by Service-In, and KRW 3,600 a share for 1,900,000 shares held by the related party. The total transaction size is KRW 16.1bn (USD 13.7m). Link to the Korean-language announcement.
31-Dec	<b>Finanza e Progetti 50% stake acquired by Servizi Italia (Source: Company Press Release(s))</b>	Servizi Italia, a company listed on the STAR segment of the Stock Market which is a leader in Italy in the integrated services of rental, laundry and sterilization of textile garments and surgical instruments for hospitals, announced the following: i. the acquisition of a 50% stake in Finanza e Progetti ("Finanza e Progetti", "FeP" or the "Company") from Lend Lease Cemea Investments ("Lend Lease" or "LL"), an Australian multinational company operating in the infrastructure field and active in Italy through the subsidiary Lend Lease (the "Acquisition") and ii.
31-Dec	<b>Eris Lifesciences' PE backer ChrysCapital plans to sell its 16% stake for up to INR 6.5bn - report (Source: Mint)</b>	ChrysCapital, the private equity (PE) fund, is planning to sell its stake in Eris Lifesciences, the Indian formulations company, mint reported, citing two sources in-the-know. The PE is expected to mandate an investment banker soon for the sale, the same sources said, adding that the sale is likely to be transacted by next year, though it was not made clear if it was referring to the next calendar year (2017) or next fiscal year (FY17), which starts in April.
30-Dec	<b>Yunnan Hongxiang Yixintang Pharmaceutical planning to raise up to CNY 2.11bn via private placement (Source: Stock Exchange Announcement (Translated))</b>	Yunnan Hongxiang Yixintang Pharmaceutical (Yixintang) [Yi Xin Tang; SHE: 002727], a China-based, listed pharmaceutical retailer group, said in a stock exchange announcement today that it is planning to raise up to CNY 2.11bn (USD 325m) via a private placement of new shares. The company plans to sell up to 37.9224m new shares at a bottom price of CNY 55.64 per share.

<b>30-Dec</b>	<b>Toshiba contacts Fujifilm Holdings for Toshiba Medical sale - report (translated) (Source: Yomiuri Shimbun)</b>	<i>Toshiba Corp. [TYO: 6502] has contacted Fujifilm Holdings Corp [TYO: 4901] for the sale of Toshiba Medical Systems Corp., a fully-owned unit engaged in the development and manufacturing of medical equipment, the Yomiuri Shimbun reported. At present, Toshiba has three or four potential buyers for the medical equipment unit, and Fujifilm Holdings is the most promising buyer among other candidates, the Japanese newspaper report said, citing unnamed sources.</i>
<b>30-Dec</b>	<b>Second People's Hospital of Chongzhou City 70% stake to be sold to Hengkang Medical Group for CNY 110m (Source: Stock Exchange Announcement (Translated))</b>	<i>Hengkang Medical Group [Heng Kang Yi Yuan; SZ:002219], a China-based, pharmaceutical company, has agreed to buy a 70% stake in The Second People's Hospital of Chongzhou City from the individual investor Zhu Zhizhong for CNY 110m (USD 17m), according to a stock exchange announcement dated 30 December. It was reported that Hengkang Medical Group signed a framework agreement in October to buy a 72.61% stake in The Second People's Hospital of Chongzhou City. Link to original source.</i>
<b>30-Dec</b>	<b>Thyrocare Technologies plans to file its draft prospectus for up to INR 5bn IPO next week - report (Source: VCCircle)</b>	<i>Thyrocare Technologies, the Indian thyroid testing company, plans to file its draft prospectus with the country's market regulator, the Securities and Exchange Board of India (Sebi), next week for an initial public offering (IPO), VCCircle reported. Citing a source in-the-know, the paper said that Thyrocare is seeking to raise between INR 4bn - INR 5bn (USD 60.4m - USD 75.5m) in its float. The source also said that the shares would be sold via an offer for sale (OFS) route. According to the report, CX Partners holds an estimated 27% stake in Thyrocare. Another 10% stake in the company is owned by Norwest Venture Partners.</i>
<b>30-Dec</b>	<b>Chularat Hospital in talks to form medical JV - report (translated) (Source: Thunhoon)</b>	<i>Chularat Hospital [BKK:CHG], a Thailand-based hospital operator, is in talks with a new partner over a potential joint venture in the medical business, Thunhoon reported.</i>
<b>29-Dec</b>	<b>Sichuan Pharmaceutical Design to be acquired by Truking Technology for USD 5m (Source: Stock Exchange Announcement (Translated))</b>	<i>Truking Technology [Chu Tian Ke Ji; SHE: 300358], a China-based pharmaceutical machinery maker, has signed an agreement to acquire 100% of Sichuan Pharmaceutical Design [Si Chuan Sheng Yi Yao She Ji Yuan] for CNY 32.98m (USD 5.08m), according to a stock exchange announcement dated 29 December.</i>
<b>29-Dec</b>	<b>Hunan Chinasun Manbing Healthcare Management 41.96% stake to be acquired by China Development Fund for CNY 72.3m (Source: Stock Exchange Announcement(Translated))</b>	<i>Hunan Chinasun Pharmaceutical Machinery [Qian Shan Yao Ji; SHE: 300216], a China-based listed medicine production equipment maker, has signed an agreement to sell a 41.96% stake in its wholly owned subsidiary Hunan Chinasun Manbing Healthcare Management to a fund managed by China Development Bank.</i>
<b>29-Dec</b>	<b>Metro Pacific Hospital acquires 20% equity stake in Manila Medical Services (Source: Stock Exchange Announcement(s) (Edited))</b>	<i>Metro Pacific Hospital Holdings Inc. (MPHHI), the hospital holding company of Metro Pacific Investments Corporation [PSE:MPI], has acquired a 20% equity stake in Manila Medical Services Inc. (MMSI), the corporation that owns and operates Manila Doctors Hospital, according to a stock exchange announcement.</i>

29-Dec	<b>Toshiba to disclose auction details for Toshiba Medical sale early next month (translated) (Source: Mainichi Shimbun)</b>	Toshiba Corp. [TYO: 6502], now under corporate-wide restructuring, plans to disclose the details of an auction for the sale of Toshiba Medical Systems Corp., a fully-owned unit engaged in the development and manufacturing of medical equipment, sometime early next month, the Mainichi Shimbun reported.
29-Dec	<b>COL Capital acquires 18.36% stake in Yangpu Zhaohu Industrial for CNY 90m (Source: Stock Exchange Announcement (Translated))</b>	COL Capital Limited (HKD: 383), the Hong Kong-listed investment holding and financial services company, announces an acquisition of equity interests in Yangpu Zhaohu Industrial Co., Ltd. On 28 December 2015 (after trading hours), Vendor I and Lianyungang Jiatai Construction Co. Ltd (Jiatai Construction) entered into the Agreement I, pursuant to which Jiatai Construction, a wholly-owned subsidiary of the Company, has conditionally agreed to acquire and Vendor I has conditionally agreed to sell 10.2% of the registered capital held by Vendor I in Yangpu Zhaohu for a consideration of CNY 50m (USD 7.7m).
29-Dec	<b>Nanjing Xinjiekou Department Store acquisition targets add a 76% stake in Shandong Qilu Stem Cell Engineering (Source: Stock Exchange Announcement (Translated))</b>	Nanjing Xinjiekou Department Store [Nan Jing Bai Huo; SHE:600682], a listed Chinese entity, announced tonight that it plans to buy a 76% stake in Shandong Qilu Stem Cell Engineering [Shan Dong Qi Lu Gan Xi Bao Gong Cheng], the operator of the only Shandong-based cord blood bank. According to the stock exchange announcement by the listed company tonight, it is in the process of planning two significant assets restructuring events.
29-Dec	<b>Indofarma to divest 20% stake in IGM unit for up to IDR 200bn (translated) (Source: Investor Daily (Indonesia))</b>	Indofarma, the listed state-owned Indonesian pharmaceutical company, is planning to divest a 20% stake in its distribution and trading unit, Indofarma Global Medika (IGM), Investor Daily reported. Indofarma aims to raise up to IDR 200bn (USD 14.6m) from the divestment, the Indonesian-language newspaper, which cited Indofarma corporate secretary Yasser Arafat, noted.
28-Dec	<b>Runda Medical Technology planning to raise up to CNY 1.3bn via private placement of new shares (Source: Stock Exchange Announcement (Translated))</b>	Shanghai Runda Medical Technology [Shang Da Yi Liao:SHA: 603108], a listed Chinese medical equipment maker, said in a stock exchange announcement dated 26 December that its board meeting has approved to raise up to CNY 1.2987bn (USD 201m) via a private placement of new shares.
28-Dec	<b>Telefield International mulls feasibility of bidding for proprietary Chinese medicines business (Source: Stock Exchange Announcement*)</b>	Telefield International (Holdings) (HKG:1143), a Hong Kong-based consumer electronic products solutions provider, announced that it is considering the feasibility of participating in the bid for a 60% stake in a target.
28-Dec	<b>Takeda to spin off long-listed products business to JV with Teva Pharmaceutical (Source: Stock Exchange Announcement (Translated))</b>	Takeda Pharmaceutical Co., Ltd. [TYO:4502] has decided to split off of its long-listed products business, spinning it off to a to-be-formed joint venture with Israeli generic drug maker Teva Pharmaceutical Industries [NYSE and TASE:TEVA] in April 2016, the Japanese pharmaceutical company said in a statement.
25-Dec	<b>Cloudnine Hospitals gets INR 4bn investment from IVFA at INR 14bn</b>	India Value Fund Advisors (IVFA) has invested INR 4bn (USD 60.64m) for buying a minority stake in Cloudnine Hospitals, a domestic infant and maternity care provider,



	<b>enterprise valuation (Source: Mint)</b>	<i>mint reported. Rohit M.A., Cloudnine's managing director, said that the sale was transacted at an enterprise value of INR 14bn.</i>
<b>25-Dec</b>	<b>Serum Institute of India plans to form JV with Russia's National Immunobiological Company (Source: Business Standard)</b>	<i>Serum Institute of India, the India-based vaccines maker, has plans to form a joint venture (JV) with National Immunobiological Company (NIC), the government-owned, Russian vaccine maker, Business Standard reported. Adar Poonawalla, CEO of Serum Institute of India, confirmed in statements to the paper that talks are now underway with Russia's health ministry for a JV.</i>
<b>24-Dec</b>	<b>Cloudnine Hospitals minority stake acquired by IVFA for INR 4bn - report (Source: The Economic Times)</b>	<i>India Value Fund Advisors (IVFA) has purchased an unspecified minority stake in Cloudnine Hospitals, a domestic infant and maternity care provider, for INR 4bn (USD 60.52m), The Economic Times reported, citing two sources with knowledge of the situation. The deal has also provided a part exit to Cloudnine Hospitals' stakeowner Matrix Partners India, which sold a part of its stake in Cloudnine Hospitals for INR 1.5bn.</i>
<b>24-Dec</b>	<b>Shanghai Fosun Pharmaceutical to establish hospital management and investment JV (Source: Stock Exchange Announcement (Translated))</b>	<i>Shanghai Fosun Pharmaceutical (HKG:2196), a listed Chinese pharmaceutical company, made the following announcement to the Hong Kong stock exchange regarding a formation of a joint venture.</i>
<b>24-Dec</b>	<b>Shanghai Kaibao Pharmaceutical to buy 20% Shanghai Yizhong Biotech stake (Source: Stock Exchange Announcement (Translated))</b>	<i>Listed company Shanghai Kaibao Pharmaceutical [Shang Hai Kai Bao; SHE: 300039] signed an agreement on 23 December to acquire a 20% stake of Shanghai Yizhong Biotech [Yi Zhong Sheng Wu Ji Shu], an anti-tumor pharmaceutical company, for CNY 131.3m (USD 20.27m). Shanghai Kaibao Pharmaceutical will invest the CNY 131.3m to raise the registered capital of Shanghai Yizhong Biotech in order to acquire the 20% stake. The listed company will fund the acquisition with IPO proceeds.</i>
<b>24-Dec</b>	<b>Unimark Remedies in talks to sell its carbapenem unit - report (Source: Financial Express)</b>	<i>Unimark Remedies, a Mumbai, India-based vertically integrated healthcare group, is now in talks to sell its carbapenem unit, Financial Express reported, citing an undisclosed company executive.</i>
<b>23-Dec</b>	<b>Anhui Fengyuan Pharmaceutical share trading halt remains, planning to purchase 100% of Eyeis in addition to Chengdu Push Pharmaceutical buy (Source: Stock Exchange Announcement (Translated))</b>	<i>Anhui Fengyuan Pharmaceutical [Feng Yuan Yao Ye] [SHE: 000153], a listed Chinese pharmaceutical company, said today its share trading halt will remain and the company is expecting to resume share trading by 13 April 2016.</i>
<b>23-Dec</b>	<b>Swiss Biological Medicine 69.84% stake acquired by Huapont-Nutrichem subsidiary for CNY 209.52m (Source: Stock Exchange Announcement (Translated))</b>	<i>Huapont-Nutrichem [Hua Bang Ying Tai; SHE: 002004], a listed Chinese chemical products company, said today its wholly owned subsidiary Tibet Linzhi Baisheng Pharmaceutical [Bai Sheng Lin Zhi] signed the agreement with the Hong Kong-based Swiss Bio-Life Technology over stake purchase in Swiss Biological Medicine on 21 December.</i>

23-Dec	<b>Humanwell Healthcare to acquire a 70% stake in Lin'an Traditional Chinese Medical Group Management for CNY 420m (Source: Stock Exchange Announcement (Translated))</b>	<i>Humanwell Healthcare [Ren Fu Yi Yao] [SHA:600079], a listed Chinese pharmaceutical company, has signed an agreement with Lin'an Guorui Health Industry Investment [Guo Rui Jian Kang], a local state-owned investment company, over forming a traditional Chinese hospital. According to the stock exchange announcement by the listed company today, it will first invest CNY 420m (USD 64.82m) in Lin'an Traditional Chinese Medicine Medical Group Management Co Ltd, a wholly owned subsidiary of Guorui Health Industry Investment, to hold a 70% stake in it. Lin'an Traditional Chinese Medicine Medical Group Management will sponsor the traditional Chinese medicine hospital, in which the listed company will invest no less than CNY 500m.</i>
23-Dec	<b>Sichuan Biokin Pharmaceutical files for CNY 574.618m Shenzhen IPO, mandates China Securities (Source: CSRC website)</b>	<i>Sichuan Biokin Pharmaceutical [Bai Li Tian Heng], a Chengdu-based, privately held pharmaceutical company, has filed a Shenzhen IPO application with the China Securities Regulatory Commission (CSRC); China Securities is the IPO sponsor/lead underwriter.</i>
22-Dec	<b>iKang Healthcare Group buys 70% stake in Xi'an iKang Health Management (Source: Company press release.)</b>	<i>iKang Healthcare Group, Inc. ("iKang" or the "Company") (Nasdaq:KANG), China's largest private preventive healthcare services provider, today announced that it has acquired 70% equity interest of Xi'an iKang Health Management, which has 100% ownership in three medical centers under the brand name of Xi'an INLUNG, namely Xi'an Lianhu INLUNG Medical Center.</i>
22-Dec	<b>Asian Institute of Gastroenterology gets USD 40m investment from Quadria Capital - report (Source: VCCircle)</b>	<i>Asian Institute of Gastroenterology, the India-based hospital company, has received a USD 40m (INR 2.65bn) investment from private equity (PE) firm Quadria Capital, VCCircle reported, citing a source in-the-know.</i>
22-Dec	<b>Toshiba planning to sell Toshiba Medical Systems (translated) (Source: Nihon Keizai Shimbun)</b>	<i>Toshiba Corp. [TYO: 6502] is planning to sell a majority stake in Toshiba Medical Systems Corp., a fully-owned unit of medical equipment developer and manufacturer, as part of its overall corporate restructuring plan announced on 21 December, the Nihon Keizai Shimbun reported.</i>
22-Dec	<b>Narayana Hrudayalaya IPO subscribed 870% at close (Source: Stock Exchange Announcement(s) (Edited))</b>	<i>The initial public offering of Narayana Hrudayalaya, the India-based operator of a cardiac hospitals chain, was 870% subscribed at the end of its final day on 21 December.</i>
22-Dec	<b>Beijing Tongrentang 10% stake acquired by Anbang Insurance (Source: Stock Exchange Announcement (Translated))</b>	<i>Beijing Tongrentang [Tong Ren Tang;SHA: 600085], a listed Chinese pharmaceutical company, disclosed in a stock exchange announcement tonight that Anbang Insurance [An Bang Bao Xian], a privately held Chinese insurance company, has acquired a 10.000002% stake in the company as of 22 December.</i>
21-Dec	<b>Auto Control Medical to be acquired by A&amp;D Company (Source: Company press release.)</b>	<i>A&amp;D Company today announced it has entered into a definitive agreement to acquire the necessary business assets of the Toronto-based Auto Control Medical. With the acquisition, Auto Control Medical will initially operate as a division of A&amp;D Canada, Inc., a subsidiary of A&amp;D Company.</i>
21-Dec	<b>Dunya Goz receives Japanese and European interest [translated] (Source: Vatan)</b>	<i>Dunya Goz Hastanesi, the Turkish hospital group, has received interest from Japanese and European investors, according to a report in Vatan.</i>

21-Dec	<b>LogiTag Systems to be acquired by Quantum Resources in option agreement (Source: Stock Exchange Announcement(s) (Edited))</b>	<i>Quantum Resources Limited [ASX: QUR] has exercised its call option under the option agreement (announced to the market on 12 November 2015) to acquire 100% of the issued capital in LogiTag Systems Limited, Quantum Resources said in a statement filed to the Australian Securities Exchange, as follows. Quantum and the seller of LogiTag have executed a binding Share Purchase Agreement (the Agreement) in respect of the acquisition.</i>
21-Dec	<b>Kaifeng Pharmaceutical acquired by Furen Pharmaceutical Group for CNY 7.85bn (Source: Stock Exchange Announcement (Translated))</b>	<i>Furen Pharmaceutical Group [Fu Ren Ji Tuan; SHA: 600781], a China-based, listed pharmaceutical company, has signed an agreement to acquire 100% of Kaifeng Pharmaceutical [Kai Feng Yao Ye] for CNY 7.85bn (USD 1.21bn), according to a stock exchange announcement posted on 21 December. Kaifeng Pharmaceutical, a company engaged in R&amp;D and sales of chemical medicine, proprietary Chinese medicine and API, is controlled by Furen Medicines Group [Fu Ren Yao Ye Ji Tuan].</i>
21-Dec	<b>Shenzhen Neptunus Interlong Bio-technique may sell Jiangsu Neptunus Bio-pharmaceutical Company Limited (Source: Stock Exchange Announcement(s))</b>	<i>Shenzhen Neptunus Interlong Bio-technique (HKG: 8329), a Hong Kong listed Chinese pharmaceutical company, announced that it has initiated a preliminary negotiation on a potential transaction which may involve the disposal of a 100% equity interest in Jiangsu Neptunus Bio-pharmaceutical Company Limited: This announcement is made by Shenzhen Neptunus Interlong Bio-technique Company Limited (the “Company” together with its subsidiaries, the “Group”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on the Growth Enterprise Market (the “GEM”) of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”) and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”).</i>
21-Dec	<b>Banner Life Sciences sells portfolio of 25 products to Bionpharma (Source: The Economic Times)</b>	<i>Bionpharma, the US-based pharma company, has acquired a drug portfolio, which comprises some 25 products, from Banner Life Sciences, the India-based specialty drug maker, The Economic Times reported. Venkat Krishnan, CEO of Bionpharma, confirmed the development, but declined to reveal financial details pertaining to the transaction.</i>
21-Dec	<b>Yantai Justaware Pharmaceutical to be sold to Fuan Pharmaceutical (Group) for CNY 1.5bn (Source: Stock Exchange Announcement (Translated))</b>	<i>Fuan Pharmaceutical (Group) [Fu An Yao Ye; SZ: 300194], a China-based listed pharmaceutical company, signed an agreement on 18 December to buy Yantai Justaware Pharmaceutical [Zhi Chu Yao Ye] from six shareholders for CNY 1.5bn (USD 231.4m), according to a stock exchange announcement.</i>
20-Dec	<b>Yantai Zhenghai Bio-Tech files Shenzhen IPO application, mandates GF Securities (Source: CSRC website)</b>	<i>Yantai Zhenghai Bio-Tech [Yan Tai Zheng Hai Sheng Wu Ke Ji], a privately held bio-medical materials company, has filed its Shenzhen IPO application with the China Securities Regulatory Commission (CSRC).</i>
20-Dec	<b>Dali Pharmaceutical files CNY 262.5m Shanghai IPO application, Citic Securities as IPO sponsor/lead (Source: CSRC website)</b>	<i>Dali Pharmaceutical [Da Li Yao Ye], a Yunnan-based privately held pharmaceutical company, has filed its Shanghai IPO application with the China Securities Regulatory Commission (CSRC); Citic Securities is the IPO sponsor/lead underwriter.</i>



18-Dec	<b>Message to be subject of tender offers by Sompō Japan Nipponkoa Holdings (Source: Company Press Release(s))</b>	Sompō Japan Nipponkoa Holdings [TYO:8630] announced today (18 December) it will launch tender offers for Message [TYO:2400]. Sompō Japan Nipponkoa Holdings (the “Company” or the “Tender Offeror”) hereby announces that it resolved.
18-Dec	<b>Sino Great Wall to form 65:35 JV with Sichuan Jiale Enterprise Group (Source: Stock Exchange Announcement (Translated))</b>	Sino Great Wall [Shen Zhou Chang Cheng; SHE:000018], a Shenzhen based textile company, has signed an agreement with privately held real estate developer Sichuan Jiale Enterprise Group to set up a joint venture, according to a stock exchange announcement. Under the agreement, both companies will set up a joint venture named Sino Jiale Medical Investment Management.
18-Dec	<b>Humanwell Healthcare and Zhongxiang government form hospital management JV (Source: Stock Exchange Announcement (Translated))</b>	Humanwell Healthcare [Ren Fu Yi Yao] [SHA:600079], a Chinese pharmaceutical company, said in a 18 December stock exchange announcement that it plans to form a hospital management joint venture (JV) with Zhongxiang government, a Hubei-based local government. Zhongxiang government will invest via its wholly owned Zhongxiang Children's Hospital in the JV to hold no less than a 34% stake in it; Humanwell Healthcare will hold no less than 51% stake in the JV with cash investment.
18-Dec	<b>EBOS to compete with TPG for Greencross stake - report (Source: Australian Financial Review)</b>	EBOS Group Ltd [NZE: EBO], a New Zealand-based provider of health and animal care services, is ready to compete with US-based private equity firm TPG for a stake in Greencross Ltd. [ASX: GXL], The Australian Financial Review reported in its Street Talk column. EBOS officials are to meet with Stuart Bruce James, Greencross chairman, in Melbourne today, the Australian newspaper report said, citing unnamed sources.
18-Dec	<b>Sompō Japan Nipponkoa to discuss acquisition of Message at board meeting on 18 Dec (Source: Stock Exchange Announcement (Translated))</b>	Sompō Japan Nipponkoa Holdings [TYO:8630], the Tokyo, Japan-based insurance company, is considering the acquisition of nursing home operator Message [TYO:2400], the insurer said in a statement filed to the Tokyo Stock Exchange.
18-Dec	<b>Telkom Indonesia unit acquires majority stake in healthcare operator Sarana Usaha Sejahtera Insan Palapa (translated) (Source: Investor Daily (Indonesia))</b>	Multimedia Nusantara, a unit of state-owned telco Telekomunikasi Indonesia (Telkom), has acquired a 75% stake in healthcare operator Sarana Usaha Sejahtera Palapa, the Indonesian-language newspaper Investor Daily reported.
18-Dec	<b>Trendlines Group establishes two new portfolio companies (Source: Stock Exchange Announcement*)</b>	In keeping with its mission to create and develop medical and agricultural technologies companies to improve the human condition, The Trendlines Group Ltd (“Trendlines” or the “Company” and together with its subsidiaries and associated companies, the “Group”) (SGX:42T) announced today that it has, via Trendlines Medical – Misgav Ltd. Established two new portfolio companies, namely Tandem Technologies Ltd. (“Tandem Technologies”) and Zeev Implants Ltd. (“Zeev Implants”) (“Establishment of Portfolio Companies”). Subsequent to the aforementioned, the number of Trendlines’ portfolio companies has increased to 47. The two medical companies are in the gastroenterology and dental markets.

18-Dec	<b>Message expected to be acquired by Sampo Japan Nipponkoa Holdings - report (translated) (Source: Nihon Keizai Shimbun)</b>	<i>Sampo Japan Nipponkoa Holdings [TYO:8630], the Tokyo, Japan-based insurance company, has solidified plans to acquire Okayama, Japan-based nursing home operator Message [TYO:2400], the Nihon Keizai Shimbun reported. Without citing sources, the Japanese-language report disclosed that Sampo, which currently holds a 3.5% stake in Message, will increase its stake to 51% or more, turning the company into a subsidiary. Sampo will make a decision on the deal by as soon as 18 December and begin the procedure for conducting the acquisition, the report said, adding that the expected value of the deal is several tens of billions of JPY (several hundreds of millions of USD).</i>
18-Dec	<b>S.Biomedics mandates KDB Daewoo Securities as IPO manager (translated) (Source: Financial News Daily (Korea))</b>	<i>S.Biomedics, a South Korean developer of cell treatment medicine, has mandated KDB Daewoo Securities as its IPO manager, the Financial News Daily reported. The Korean-language newspaper cited CEO Chang-hee Hahn as saying that the company aims to grow as the best cell treatment drug developer in the country after finalizing the planned initial public offering.</i>
18-Dec	<b>GYT Traditional Chinese Medicine files CNY 472m Shanghai IPO, mandates Guotai Junan Securities as sponsor (Source: CSRC website)</b>	<i>GYT Traditional Chinese Medicine [Guang Yin Tang Zhong Yao], an Anhui-based privately held pharmaceutical company, has filed its Shanghai IPO application with the China Securities Regulatory Commission (CSRC); Guotai Junan Securities is the IPO sponsor/lead underwriter.</i>
18-Dec	<b>Sannova drug manufacturing and sales business to be spun off to Alfresa Holdings (Source: Stock Exchange Announcement (Translated))</b>	<i>Alfresa Holdings [TYO:2784], the Tokyo, Japan-based pharmaceutical company, announced today it will acquire the drug manufacturing and sales business that is to be split off from Gunma, Japan-based Sannova, a subsidiary of pharmaceutical company Eisai [TYO:4523].</i>
18-Dec	<b>Zhenxing Group to increase stake in Zhenxing Biopharmaceutical &amp; Chemical from 22.61% to 43.51% (Source: Stock Exchange Announcement (Translated))</b>	<i>Chinese conglomerate Zhenxing Group will increase its stake in Zhenxing Biopharmaceutical &amp; Chemical [S*ST Sheng Hua] [SHE:000403], a China-based listed pharmaceutical company, from 22.61% to 43.51%, via subscribing to new shares to issued by the listed company. According to a stock exchange announcement posted by Zhenxing Biopharmaceutical &amp; Chemical, it has signed a conditional agreement with Zhenxing Group.</i>
18-Dec	<b>Beijing Pharmaceutical Group puts Anhui Worldbest Pharmaceutical 60% stake up for sale at CNY 269.3m (Source: Chinese Equity Exchange Announcement)</b>	<i>Beijing Pharmaceutical Group [Bei Yi Gu Fen], a Beijing-based state-owned pharmaceutical products company, has put a 60% stake of Anhui Worldbest Pharmaceutical up for sale with an asking price of CNY 269.343m (USD 41.54m), according to a 17 December announcement posted on the Shanghai United Assets and Equity Exchange. Anhui Worldbest Pharmaceutical, a China-based medicine distributor, has a registered capital of CNY 60m.</i>
17-Dec	<b>Vital Healthcare Property to consider acquisition opportunities (Source: Stock Exchange Announcement(s) (Edited))</b>	<i>Vital Healthcare Property [NZX:VHP], a New Zealand-based hospital owner, has repriced AUD 225m of banking facilities, which will allow the group headroom for acquisition opportunities, according to a stock exchange announcement. Vital Healthcare Management ('Manager'), the manager of Vital Healthcare Property Trust ('Vital'), today announced that it had favourably repriced and extended its existing</i>

bank facilities on more competitive terms and added an additional AUD 100m tranche expiring October 2020.

17-Dec	<b>Shanxi Pude Pharmaceutical 14.99% stake to be sold to Harbin Gloria Pharmaceuticals for USD 59.6m (Source: Stock Exchange Announcement (Translated))</b>	Harbin Gloria Pharmaceuticals [Yu Heng Yao Ye] [SHE: 002437] signed an agreement on 17 December to acquire a 14.99% stake in Shanxi Pude Pharmaceutical [Pu De Yao Ye], a privately held pharmaceutical company, for CNY 386.72m (USD 59.6m). According to a stock exchange announcement, Shanxi Pude Pharmaceutical reported revenues of CNY 535.2m and a net profit of CNY 172m in 2014. As reported, Harbin Gloria Pharmaceuticals has acquired an 85.01% stake in Shanxi Pude Pharmaceutical for CNY 2.389bn. <a href="#">Link to original source.</a>
17-Dec	<b>Health Biomed files Shanghai IPO, mandates Credit Suisse Founder as sponsor (Source: CSRC website)</b>	Health Biomed [Hai Er Shi Sheng Wu Yi Yao], a privately held diagnostic products company in Ningbo, Zhejiang Province, has filed its Shanghai IPO application with the China Securities Regulatory Commission (CSRC); Credit Suisse Founder has been mandated as the IPO sponsor/lead underwriter. According to the company filing on the CSRC website tonight, the company plans to sell up to 69m new shares via the initial public offering, with the aim of raising CNY 1.38bn (USD 213m) to fund its production.
17-Dec	<b>MYOS to receive up to USD 30.4m investment from RENS Agriculture Science &amp; Technology (Source: Company press release.)</b>	MYOS Corporation ("MYOS" or the "Company") (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that it has entered into a securities purchase agreement with RENS Technology Inc. (the "Investor"), a wholly-owned subsidiary of RENS Agriculture Science & Technology Co. Ltd ("RENS Agriculture"), pursuant to which the Investor will invest up to USD 30.375m in MYOS as described below (the "Financing"). In connection with the Financing, the Investor will purchase.
16-Dec	<b>Shanghai Fosun Pharmaceutical, Qingdao City Construction Investment to form 50/50 hospital management JV (Source: Stock Exchange Announcement (Translated))</b>	Shanghai Fosun Pharmaceutical (SHA: 600303; HKG:2196), a listed Chinese pharmaceutical company, said its wholly owned subsidiary Shanghai Fosun Hospital Management has signed an agreement with Qingdao City Construction Industrial Investment over forming a hospital management JV. According to the stock exchange announcement by the listed company, Qingdao Shanda Qilu Hospital Investment & Management [Qing Dao Shan Da Qi Lu Yi Yuan Tou Zi Guan Li], the JV, is expected to have registered capital of CNY800m (USD 123.58m).
16-Dec	<b>Shenzhen Universe in talks over buying Shenzhen Youdeyi Technology and Shenzhen Yiyitong Technology (Source: Stock Exchange Announcement (Translated))</b>	Shenzhen Universe [Shen Tian Di; SHE::000023], a China-based listed concrete products maker, said in a stock exchange announcement today that it is in talks over buying part or all of the stake in two privately held online medical information system platform companies via a new share issuance.
16-Dec	<b>Healthscope/AUX deal was blocked by FIRB earlier this year - report (Source: Australian Financial Review)</b>	Australia's Foreign Investment Review Board (FIRB) blocked an effort by China's AUX Group to buy the stake in Healthscope [ASX:HSO] owned by TPG and The Carlyle Group earlier this year, the Australian Financial Review reported. According to the report in the paper's Street Talk column, TPG and Carlyle were reportedly in talks to

sell a portion of their AUD 2.7bn (USD 1.9bn) holding to AUX for several months, before ultimately selling down via a block trade on 23 November.

<b>16-Dec</b>	<b>Huaren Pharmaceutical to halt share trading on 17 December, board will discuss significant assets restructuring (Source: Stock Exchange Announcement (Translated))</b>	Huaren Pharmaceutical [Hua Ren Yao Ye; SHE:300110], a Shandong-based, listed pharmaceutical company, will enter into a share trading halt on 17 December as its board will discuss a significant assets restructuring event. According to the company stock exchange announcement, it is expecting to resume share trading on 21 December. Huaren Pharmaceutical has a market cap of CNY 12.214bn (USD 1.887bn). <a href="#">Link to Stock exchange announcement.</a>
<b>16-Dec</b>	<b>AstraZeneca to acquire Takeda's core respiratory business for USD 575m (Source: Stock Exchange Announcement(s) (Edited))</b>	AstraZeneca today announced that it has entered into a definitive agreement to acquire the core respiratory business of Takeda Pharmaceutical Company Limited ("Takeda"). The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD). AstraZeneca has marketed Daliresp in the US since the acquisition of the rights from Actavis in the first quarter of 2015.
<b>16-Dec</b>	<b>Godrej Agrovet acquires additional 6.99% stake in Astec Lifesciences through open offer (Source: Stock Exchange Announcement(s) (Edited))</b>	Astec Lifesciences [BOM:533138] has announced the following on the Bombay Stock Exchange, pertaining to the post open offer shareholding status in the company following the recent tender by Godrej Agrovet: Godrej Agrovet acquired an additional 6.99% stake in Astec Lifesciences by way of the open offer Post offer shareholding of acquirer stands at 55.29% "Kotak Mahindra Capital Company Limited ('Manager to the Offer').
<b>15-Dec</b>	<b>Jayex Healthcare listing on ASX to raise AUD 8m (Source: Company Press Release*)</b>	Jayex Healthcare is planning to issue 25m shares at AUD 0.32 per share to raise up to AUD 8m (USD 5.6m), according to the company's prospectus. On listing the business expects to have a market capitalisation of AUD 48.3m. The full prospectus dated 3 November can be found <a href="#">here</a> .
<b>15-Dec</b>	<b>Citychamp Dartong subsidiary, Huaian Hospital of Traditional Chinese Medicine to form an 85/15 hospital JV (Source: Stock Exchange Announcement (Translated))</b>	Citychamp Dartong [Guan Cheng Da Tong] [SHE:600067], a listed, China-based real estate company, said in a stock exchange announcement today that its subsidiary plans to form a hospital JV with Huaian Hospital of Traditional Medicine [Huai An Zhong Yi Yuan], a Jiangsu-based state-owned hospital. Citychamp Dartong (Hong Kong), a wholly owned subsidiary of the listed company, plans to form a medical investment subsidiary in Huaian City, Huaian Citychamp Medical Investment Management [Huai Ai Guan Cheng Yi Liao Tou Zi Guan Li], which will have a registered capital of USD 33m.
<b>15-Dec</b>	<b>Greencross hires Macquarie Capital, Allier Capital as advisers after reported plan of private equity firm to take up to 15% stake (Source: Stock Exchange Announcement(s) (Edited))</b>	Greencross Ltd. [ASX: GXL] has appointed Macquarie Capital (Australia) Limited and Allier Capital as financial advisers, the company said in a statement filed to the Australian Securities Exchange.
<b>15-Dec</b>	<b>Vibhavadi Medical Center to acquire hospital in next five years;</b>	Vibhavadi Medical Center [BKK:VIBHA], a Thailand-based hospital group, expects at least one hospital acquisition in the coming five years, Thunhoon reported.



	<i>in talks over JVs (translated) (Source: Thunhoon)</i>	
15-Dec	<b>Modern Dental Group will use acquisitions for business expansion (translated) (Source: Hong Kong Economic Journal)</b>	Modern Dental Group (HKG: 3600), a global dental prosthetic device provider, will use acquisitions as a means to expand its business, the Hong Kong Economic Journal reported. The Chinese language news report, citing CEO Ngai Shing Kin, said the company plans to use the majority of its IPO proceeds for making strategic acquisitions both in China and overseas markets, as well as for the establishment of new manufacturing base. He added that the firm will consider acquiring small-scale processing plants in order to expand its business and enhance its market share.
15-Dec	<b>Meinian consortium announces improved USD 23.50 per ADS proposal for iKang (Source: Company Press Release(s))</b>	Jiangsu Sanyou Group Co Ltd (SZSE: 002044, "Jiangsu Sanyou", also known as Meinian Onehealth Healthcare (Group) Co., Ltd) today announces that the consortium of which it is a member ("the Consortium" or "We") has submitted a revised and improved proposal (the "Improved Proposal") to acquire iKang Healthcare Group, Inc. (NASDAQ: KANG, "iKang").
15-Dec	<b>Cotech Bio-tech to be sold to Hangzhou Tianmushan Pharmaceutical for CNY 1.25bn (Source: Stock Exchange Announcement (Translated))</b>	Hangzhou Tianmushan Pharmaceutical [Tian Mu Shan;600671.SHA], a China-based pharmaceuticals company, has signed an agreement to acquire Liaoning Cotech Bio-gen [Ke Tai Sheng Wu] for CNY 1.25bn (USD 193.4m), according to a stock exchange announcement on 15 December.
15-Dec	<b>Regent Pacific reaches agreement on terms of recommended offer to acquire Plethora (Source: Stock Exchange Announcement(s) (Edited))</b>	The Regent Pacific Board and the Independent Plethora Director are pleased to announce that they have reached agreement on the terms of a recommended share-for-share offer pursuant to which Regent Pacific will acquire the entire issued and to be issued ordinary share capital of Plethora not already directly or indirectly owned by Regent Pacific (the "Offer"). It is proposed that the Offer will be effected by means of a scheme of arrangement of Plethora under Part 26 of the Companies Act (although Regent Pacific reserves the right to effect the Offer by way of a takeover offer).
15-Dec	<b>Northeast Tiger Pharmaceutical may receive general offer from an independent third party (Source: Business Standard)</b>	Northeast Tiger Pharmaceutical [HKG:8197], a Hong Kong-listed medicine products manufacturer, announced that it may receive a mandatory unconditional general offer from an independent third party.
14-Dec	<b>Narayana Health to conduct IPO from 17 to 21 December (Source: Stock Exchange Announcement(s) (Edited))</b>	Narayana Health, the India-based operator of a cardiac hospitals chain, will conduct its IPO from 17 December 2015 to 21 December 2015. This information is available on the BSE website. The IPO is of 24,523,297 shares in a price range of INR 245-INR 250 (USD 3.653-USD 3.728) each. <a href="#">Link to original source</a>
14-Dec	<b>E for L Aim plans to file for unit listing in February 2016 (translated) (Source: Thunhoon)</b>	E for L Aim [BKK:EFORL], a Thailand-based medical equipment distributor, plans to file for the listing of its beauty clinic unit Wuttisak Clinic Inter Group (WCIG) in February 2016, Thunhoon reported. The company expects to see WCIG start trading on the Stock Exchange of Thailand in 2Q16, the Thai-language report said, citing E for L Aim CEO Thirawut Pangwirunrak.



14-Dec	<b>Modern Dental Group nets HKD 664.5m through Hong Kong IPO (Source: Stock Exchange Announcement(s))</b>	<i>Modern Dental Group, a global dental prosthetic device provider, announced that it has raised net proceeds of approximately HKD 664.5m (USD 85.7m) through its IPO in Hong Kong, after pricing the share at HKD 4.2 per share.</i>
14-Dec	<b>Sun Pharmaceutical Industries subsidiary to sell Ohio manufacturing unit to Nostrum Laboratories (Source: Company Press Release(s) (Edited))</b>	<i>The India-based Sun Pharmaceutical Industries [BOM:524715] (Sun Pharma) on 14 December 2015 announced that as a part of its manufacturing consolidation in the US, one of its wholly owned subsidiaries has entered into an agreement with Nostrum Laboratories (Nostrum) for the divestment of the Bryan (Ohio) unit in the US. As a part of the agreement, the Sun Pharma subsidiary has divested this unit as a going concern along with the employees and related products to Nostrum. During the divestment process, Sun Pharma was cognizant that the interests of its employees working in the unit were not compromised. While other details of the transaction are confidential, the financial impact of this development on Sun Pharma is negligible.</i>
14-Dec	<b>Athenex acquires Comprehensive Drug Enterprises (Source: Company Press Release*)</b>	<i>Athenex, Inc. announces the closing of the acquisition of Comprehensive Drug Enterprises (CDE), based in Hong Kong's Science Park, in a stock for stock transaction that closed in July 2015.</i>
14-Dec	<b>Biokom 100% acquisition by Lupin approved by Russia's government commission (Source: Government Press Release*)</b>	<i>Russia's Government Commission on Monitoring Foreign Investment has approved the acquisition of a 100% stake in Biokom (Biocom) by Lupin Ltd, according to an announcement posted on the Russian government website on 11 December. The portion of a press release, citing Federal Anti-Monopoly Service Head Igor Artemyev, reads as follows: Briefing by Federal Anti-Monopoly Service Head Igor Artemyev Lupin Ltd, a major Indian pharmaceutical company, will acquire a 100% stake in Biokom, a Russian pharmaceutical company. Biokom produces 17 digestive, nervous, musculoskeletal system drugs that are on the Russian list of vital medications.</i>
14-Dec	<b>Hugel IPO price finalized at KRW 150,000 per share, below the down end of guidance band (Source: Stock Exchange Announcement (Translated))</b>	<i>Hugel, a South Korean botulinum toxin manufacturer, has finalized the share price of its IPO at KRW 150,000, according to a stock exchange statement. The total IPO size is KRW 54bn (USD 45.6m). The subscription will be open for two days from 15 December. The lead underwriters for the IPO are KB Investment &amp; Securities and KDB Daewoo Securities.</i>
14-Dec	<b>Beijing Jialin Pharmaceutical to conduct backdoor listing via Xinjiang Tianshan Wool Tex (Source: Stock Exchange Announcement (Translated))</b>	<i>China-based listed Xinjiang Tianshan Wool Tex [Tian Shan Fang Zhi; SHE:000813] signed an agreement on 12 December pursuant to which Beijing Jialin Pharmaceutical will conduct a backdoor listing, according to a stock exchange announcement. The deal includes four parts - asset swap, acquiring assets via issuing new shares, stake transfer and capital raise.</i>
13-Dec	<b>Archer Capital pursuing dividend recapitalization of Allity - report (Source: Australian Financial Review)</b>	<i>Archer Capital is pursuing a dividend recapitalization of Allity, the Australian age-care provider, reported the Australian Financial Review's Street Talk column. The unsourced report noted that the deal will allow Archer to exchange a portion of its equity with new debt.</i>
13-Dec	<b>Primary Health Care attracts consortium of Singapore and Chinese bidders for possible break</b>	<i>A consortium of Singapore and Chinese bidders is considering a break up of Primary Health Care [ASX: PRY], the Australian Financial Review reported. The Street Talk column, citing multiple sources, said that a Singapore-government back entity,</i>

	<b>up - report (Source: Australian Financial Review)</b>	possibly GIC, is collaborating with several partners in China for a break up of Primary Health Care.
<b>13-Dec</b>	<b>Guangzhou International Medicine Port 33% placed for sale, initial bidding price set at CNY 1.184bn (Source: Chinese Equity Exchange Announcement)</b>	A 33% stake of Guangzhou International Medicine Port [Guo Ji Yi Yao Gang], a Guangdong, China-based medicine trading and distribution company, has been placed for sale by state-owned company Guangdong Medicine Group Corporation on the Southern United Assets & Equity Exchange.
<b>11-Dec</b>	<b>Xiamen Comfort Science and Technology to halt trading over planned acquisition of overseas company (Source: Stock Exchange Announcement (Translated))</b>	Xiamen Comfort Science and Technology [Meng Fa Li; SHE: 002614], a China-based healthcare equipment manufacturer, disclosed in a stock exchange announcement on 11 December that it will enter into a trading halt on 14 December due to a planned acquisition of an overseas firm. <a href="#">Link to original source.</a>
<b>11-Dec</b>	<b>Cloudnine Hospitals 35% stake may be acquired by IVFA for USD 68m - report (Source: Mint)</b>	India Value Fund Advisors (IVFA) is now in talks for buying a 35% stake in Cloudnine Hospitals, a domestic infant and maternity care provider, for INR 4.5bn (USD 68m), the mint reported, citing two sources in the know. Cloudnine Hospitals' existing shareholders Sequoia Capital and Matrix Partners India will partially sell their stakes, one of the sources said, adding that besides the investors, the Cloudnine owner will also sell an estimated 10% stake. The other source was cited as saying that IVFA would buy the stake at an enterprise value of INR 13.5bn (USD 201.8m).
<b>11-Dec</b>	<b>China Jiu hao Health issues 6.8bn shares representing 51% of issued capital to Huayi Brothers, Tencent Holdings and others (Source: Stock Exchange Announcement (Translated))</b>	China Jiu hao Health Industry (HKG: 0419), the Hong Kong-listed healthcare company, made the following announcement to the stock exchange: Reference is made to the Rule 3.7 Announcement and the Update Announcements, pursuant to which the Company initially announced the proposed subscription for convertible securities or preferred shares in the Company convertible into approximately 88% of the Enlarged Issued Share Capital with certain potential investors at a subscription price of no less than HKD 0.08 a share. The Company has renegotiated with the investors in respect of certain terms and conditions of the proposed subscription and is now pleased to announce as follows.
<b>11-Dec</b>	<b>Xuyi Hengshan Chinese Medicine Hospital 25.08% stake to be acquired by Hengkang Medical Group (Source: Stock Exchange Announcement (Translated))</b>	Hengkang Medical Group (Heng Kang Yi Liao) [SHE:002219], a listed Chinese pharmaceutical and healthcare company, signed an agreement on 10 December to acquire a 25.08% stake of Xuyi Hengshan Chinese Medicine Hospital, according to a stock exchange announcement.
<b>11-Dec</b>	<b>Chinese buyer rumored to be targeting ASX-listed healthcare company - report (Source: Australian Financial Review)</b>	A China-based buyer is said to be targeting an ASX-listed healthcare company, the Australian Financial Review's Street Talk reported. The paper cited unnamed sources as saying that the buyer is seeking a non-controlling stake and that talks are in a very preliminary stage. The paper said that sources have ruled out Primary Health Care

*[ASX:PRY] as a possible target due to its difficult relationship with doctors. Other possible targets include Virtus Health [ASX:VRT], Monash IVF [ASX:MVF].*

<b>11-Dec</b>	<b>Northeast Tiger Pharmaceutical in trading halt pending announcement relating to change of controlling shareholder (Source: Stock Exchange Announcement*)</b>	Northeast Tiger Pharmaceutical (HKG: 8197), a Hong Kong-listed medicine products manufacturer, made the following announcement to the Hong Kong stock exchange: At the request of Northeast Tiger Pharmaceutical Co., Ltd.* (the “Company”), trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been halted with effect from 11:33 a.m. on 11 December 2015, pending the release of an announcement by the Company in relation to inside information and change of the controlling shareholder of the Company.
<b>11-Dec</b>	<b>Duoduo Pharmaceutical 78.82% stake to be sold to Beijing Zhongguancun Sihuan Pharmaceutical (Source: Stock Exchange Announcement (Translated))</b>	Beijing Zhongguancun Sihuan Pharmaceutical signed an agreement on 10 December to acquire a 78.82% stake in Duoduo Pharmaceutical [Duo Duo Yao Ye] for CNY 309.28m (USD 48m) in total, according to a stock exchange announcement posted by Beijing Centergate Technologies (Holding) [Zhong Guan Cun; SZ: 000931]. Beijing Zhongguancun Sihuan Pharmaceutical is a subsidiary of Beijing Centergate Technologies (Holding), a listed company engaged in real estate and pharmaceuticals.
<b>11-Dec</b>	<b>Jiangzhong Pharma signs agreement to sell 51% stake in Jiangxi Jointown to Jointown Pharmaceutical (Source: Stock Exchange Announcement (Translated))</b>	Jiangzhong Pharmaceutical [Jiang Zhong Yao Ye; SHA: 600750], a listed Chinese company, signed an agreement on 9 December to transfer a 51% stake in Jiangxi Jointown Pharmaceutical, a sales company, to Jointown Pharmaceutical [Jiu Zhou Tong; SHA: 600998], according to a stock exchange announcement. The announcement, made on 10 December, said the deal value is set at CNY 66.73m (USD 10.5m).
<b>10-Dec</b>	<b>Asiri Hospital Holdings 28% stake acquired by TPG Growth from Actis (Source: Company Press Release*)</b>	TPG Growth, the middle market and growth-equity investment platform of leading global private investment firm TPG, today announced the acquisition of a 28% stake in Asiri Hospital Holdings (Asiri) from Actis, a leading emerging markets private equity investor. Asiri is the largest multi-speciality private healthcare business in Sri Lanka, which is controlled by the dynamic Softlogic group led by Ashok Pathirage. “TPG is one of the leading investors in healthcare globally, with an accomplished team of investment professionals, operators and technical experts who identify and execute on great opportunities in the sector,” said Bill McGlashan, Managing Partner of TPG Growth.
<b>10-Dec</b>	<b>Shenyang Aohua Pharmaceutical to be sold to Yifan Xinfu Pharmaceutical subsidiary for USD 11m (Source: Stock Exchange Announcement (Translated))</b>	Hefei Yifan Bio-Pharm, a fully owned subsidiary of China-based listed Yifan Xinfu Pharmaceutical [Yi Fan Xin Fu; SHE: 002019], signed an agreement on 10 December to acquire 100% of Shenyang Aohua Pharmaceutical for CNY 71.42m (USD 11m), according to a stock exchange announcement.
<b>10-Dec</b>	<b>Sichuan Tianlian Pharmaceutical selling to Yifan Xinfu Pharmaceutical for CNY 303m (Source: Stock Exchange Announcement (Translated))</b>	Yifan Xinfu Pharmaceutical [Yi Fan Xin Fu; SHE: 002019], a China based listed pharmaceutical company, signed an agreement on 10 December to buy 100% of Sichuan Tianlian Pharmaceutical [Tian Lian Yao Ye] for CNY 303m (USD 47m), according to a stock exchange announcement. Sichuan Tianlian Pharmaceutical is a dermatological medicine developer owned by individual investor Zhang Yingting and Ningbo Bonded Area Dachang Medical Investment Partnership. Sichuan Tianlian

reported revenue of CNY 13.3m and net profit of CNY 0.84m in 2014. [Link to original source.](#)

10-Dec	<b>Wuyi International Pharmaceutical to acquire Fujian Liumai Medical Services for HKD 145m (Source: Stock Exchange Announcement*)</b>	<p>Wuyi International Pharmaceutical (HKG: 1889), a Chinese mainland-based drug maker, announced that it has signed an agreement to acquire Fujian Liumai Medical Services Co., Ltd for HKD 145m (USD 18.7m): In order to promote the academic recognition of the products of the Group and enhance the awareness of the products of the Group, effectively facilitate the expansion of the Group's market share in the pharmaceutical industry throughout the PRC, and generate synergy in areas including distribution channels for pharmaceutical products and the daily operation and management of the Group, laying a solid foundation for the transformation of the Group from a traditional pharmaceutical products manufacturer into a modern pharmaceutical service provider, on 9 December 2015 (after trading hours), the Company, the Purchaser (an indirect wholly-owned subsidiary of the Company), the Target Company.</p>
09-Dec	<b>Greencross may interest private equity suitors - report (Source: Australian Financial Review)</b>	<p>Greencross [ASX: GXL], the Australian veterinary group, could be of interest to private equity buyers, the Australian Financial Review's Street Talk reported. The unsourced article noted that Greencross' market value has halved over the last six months.</p>
09-Dec	<b>Nanjing Xinjielou Department Store stock trading halt stays; company plans to buy China Cord Blood, Sanpower assets and An Kang Tong (Source: Stock Exchange Announcement (Translated))</b>	<p>Nanjing Xinjielou Department Store [Nan Jing Bai Huo; SHE:600682], a listed Chinese entity, announced tonight that the halt in its stock trading will continue and it expects to announce details of a plan on two significant assets restructuring events by 5 January. According to the stock exchange announcement, the department store operator has signed a framework agreement with Golden Meditech [Jin Wei Yi Liao, HKG: 0801] to acquire a 65.1% stake in China Cord Blood [NYSE:CO], a listed provider of cord blood collection, laboratory testing, hematopoietic stem-cell processing and stem-cell storage services. The 65.1% stake is valued at about CNY 7.255bn (USD 1.14bn).</p>
09-Dec	<b>Suzhou Tianma Specialty Chemicals may see change in controlling shareholder (Source: Stock Exchange Announcement (Translated))</b>	<p>Suzhou Tianma Pharma Group, the controlling shareholder of Suzhou Tianma Specialty Chemicals [Tian Ma Jing Hua] [SHE:002453] plans to sell a stake in the China-based listed fine chemical, API and paper-making chemical producer, according to a stock exchange announcement dated 9 December. Suzhou Tianma Pharma Group holds a 20.67% stake in Suzhou Tianma Specialty Chemicals. The proposed stake sale may lead to change in controlling shareholder of the listed company.</p>
08-Dec	<b>Hengkang Medical to buy remaining 30% stake in Wafangdian No. 3 Hospital (Source: Stock Exchange Announcement (Translated))</b>	<p>Hengkang Medical Group [Heng Kang Yi Yuan; SHE:002219], a China-based, listed pharmaceutical company, has signed an agreement to acquire the 30% stake of Wafangdian No. 3 Hospital that it already does not own from 44 individuals for CNY 215.475m (USD 33.6m). According to a stock exchange announcement posted on 8 December, Wafangdian No. 3 Hospital booked revenue of CNY 201.3m and net profit of CNY 19.11m in 1H15. The hospital had total asset of CNY 694.7m and debt of CNY 482.6m as of 30 June 2015. It was reported that Hengkang Medical Group acquired a 70% stake in Wafangdian No. 3 Hospital in 2014 for around CNY 500m. <a href="#">Link to original source.</a></p>



08-Dec	<b>Dr. Lal Pathlabs allots 3.48 million shares at INR 550 apiece to anchor investors for INR 5.5bn (Source: Company Press Release(s) (Edited))</b>	<i>Dr. Lal Pathlabs, an India-based diagnostics company, has announced the following, related to the allocation of 3.48 million equity shares at INR 550 per equity share aggregating to INR 1.91bn to Anchor Investors: "Dr Lal PathLabs Limited ("Company" or "Issuer") has finalized the allocation of 3,480,000 Equity Shares at INR 550 (upper end of the Price Band) per Equity Share aggregating to INR 191 crore to Anchor Investors.</i>
08-Dec	<b>Rowsley signs MOU for strategic partnership with Thomson Medical for a USD 1.1bn project (Source: Stock Exchange Announcement*)</b>	<i>Rowsley (SGX: A50), the Singapore listed real estate and hospitality company, has signed a MOU for a strategic partnership with Thomson Medical for a MYR 5bn (USD 1.1bn) project, according to a stock exchange announcement. Rowsley Ltd. and Thomson Medical Pte. Ltd. today signed a Memorandum of Understanding (MOU) for Thomson Medical to be Rowsley's strategic partner in the MYR 5bn Vantage Bay Healthcare City project in Iskandar in southern Malaysia. Rowsley and Thomson Medical will work together to conceptualize and develop the project.</i>
08-Dec	<b>YiChang HEC ChangJiang Pharmaceutical seeks up to USD 300m Hong Kong IPO - report (translated) (Source: Infocast News)</b>	<i>YiChang HEC ChangJiang Pharmaceutical, a Chinese pharmaceuticals manufacturing company, plans to raise USD 200m – USD 300m through a Hong Kong listing, the Infocast News reported. The Chinese language news report, citing an undisclosed market source, said YiChang HEC will kick off IPO roadshows next week and aims to list on the Hong Kong stock exchange before the year end. CICC is the sponsor on the share offer, the report noted. Link to original source.</i>
08-Dec	<b>ASLAN Pharmaceuticals raises USD 34m Series C investment from Accuron Technologies (Source: Company Press Release(s))</b>	<i>ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, has secured USD 34m in a Series C financing. The financing was led by Accuron Technologies Limited, a wholly-owned subsidiary of Temasek Holdings. Accuron is a global technology and engineering group with a leading global medical device and diagnostics business division – Accuron MedTech. Other new investors included Tianda Pharmaceuticals Limited and Haitong International.</i>
07-Dec	<b>Pulse Health acquires six Australian facilities and the Boulcott Hospital (Source: Stock Exchange Announcement)</b>	<i>Pulse Health Limited [ASX: PHG], the Australian hospital operator, has acquired six Australian facilities and the Boulcott Hospital, a New Zealand-based medical facility, according to a stock exchange announcement. Pulse Health is pleased to announce that it has entered into an agreement to acquire five day surgeries and an acute hospital (Australian Facilities) providing a quality platform for expansion in the attractive endoscopy centre market. Further, Pulse is pleased to announce that it has entered into an agreement with Evolution Healthcare to acquire Boulcott Hospital in Wellington, New Zealand. The purchase price for the Australian Facilities and Boulcott consists of AUD 48.3m (USD 35.1m) in upfront consideration and potential earn-outs subject to FY16 and FY17 EBITDA growth. The full announcement can be seen here.</i>
07-Dec	<b>U-Home Group signs memorandum for 60% stake purchase in La Clinique de Paris International for maximum consideration of HKD 150m</b>	<i>U-Home Group Holdings (HKG: 2327) announced that it has signed a memorandum for the acquisition of a 60% stake in La Clinique de Paris International for a maximum consideration of HKD 150m (USD 19.4m). The announcement is made by U-Home Group Holdings (the "Company", together with its subsidiaries, collectively referred to as the "Group") pursuant to Rule 13.09 of the Rules (the "Listing Rules") Governing the</i>



	<b>(Source: Stock Exchange Announcement*)</b>	<i>Listing of Securities on The Stock Exchange of Hong Kong (the “Stock Exchange”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Reference is made to the announcement issued by the Company dated 2 November 2015 (the “Announcement”) in relation to the Proposed Acquisition.</i>
<b>07-Dec</b>	<b>Luye Medical Group to acquire Healthe Care for USD 688m (Source: Company Press Release (Translated))</b>	<i>China’s Luye Medical Group has signed an agreement to acquire Healthe Care Australia Pty Limited, Australia’s third-largest private hospital operator, from Archer Capital Fund for USD 688m. Healthe operates 17 private hospitals in Australia with annual sales of around CNY 3bn (USD 468.5m). Luye chairman Liu Dian Bo said the acquisition of Healthe Care will provide the company with a platform to build an advanced healthcare services business in Australia, China and other Asian countries.</i>
<b>07-Dec</b>	<b>Pulse Health to raise AUD 42.5m in placement, 2-for-5 entitlement offer (Source: Stock Exchange Announcement (Translated))</b>	<i>Pulse Health Limited [ASX: PHG], will raise AUD 42.5m (USD 31.2m) in a combination of a share placement and a 2-for-5 pro rata accelerated non-renounceable entitlement offer, the company said in a statement filed to the Australian Securities Exchange.</i>
<b>07-Dec</b>	<b>Jiangxi Jointown Pharmaceutical 51% stake to be acquired by Jointown (Source: Stock Exchange Announcement (Translated))</b>	<i>Jiangzhong Pharmaceutical [Jiang Zhong Yao Ye; SHA: 600750], a listed Chinese company, said in a stock exchange announcement made tonight that a 51% stake in Jiangxi Jointown Pharmaceutical will be acquired by Jointown Pharmaceutical [Jiu Zhou Tong]. Jiangxi Jointown is a joint venture formed by the listed company and Jointown, a China-based pharmaceuticals sales company, on a 51:49 basis.</i>
<b>07-Dec</b>	<b>U-Home Group in trading halt pending announcement relating to a possible acquisition (Source: Stock Exchange Announcement(s))</b>	<i>U-Home Group Holdings (HKG: 2327) has made the following announcement to the Hong Kong Stock Exchange: At the request of U-Home Group Holding Limited (the “Company”), trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended from 9:00 a.m. on 7 December 2015 pending the release of the announcement relating to a possible acquisition and investment in relation to a memorandum of understanding signed on 6 December 2015 by the Company, which requires disclosure under the Inside Information Provisions (as defined in the Listing Rules).</i>
<b>07-Dec</b>	<b>Inner Mongolia Furui Medical Science plans to acquire a pharmaceutical firm (Source: Stock Exchange Announcement (Translated))</b>	<i>Inner Mongolia Furui Medical Science [Fu Rui Gu Fen] [SHE:300049], an Inner Mongolia-based listed pharmaceutical company, is planning to acquire a peer company via issuing new shares, according to a stock exchange announcement. Share price of Inner Mongolia Furui Medical Science closed at CNY 31 per share on 27 November, valuing the listed company at CNY 8.167bn (USD 1.275bn).</i>
<b>07-Dec</b>	<b>Lee’s Pharmaceutical awaiting suitable acquisition opportunities (translated) (Source: Hong Kong Economic Journal)</b>	<i>Lee’s Pharmaceutical Holdings [HKG:950], a Hong Kong-based drug maker, is awaiting suitable acquisition opportunities, the Hong Kong Economic Journal reported. The Chinese-language news report, citing CEO Lee Siu Fong, said the reform in the pharmaceutical industry in China will likely give rise to abundant acquisition opportunities, and more takeover activities are expected.</i>
<b>07-Dec</b>	<b>Kingworld Medicine believes there will be some acquisition opportunities over next two years</b>	<i>Kingworld Medicine Group [HKG:1110], a China-based health and medical products distributor, believes there will be some acquisition opportunities in the next one to two years, the Hong Kong Economic Journal reported. The Chinese language news report,</i>

*(translated) (Source: Hong Kong Economic Journal)*

*citing financial controller Chan Hon Wan, said the company has recently signed a strategic cooperation agreement with Sinopharm Capital Management, and such a strategic cooperation will help the company identify acquisition opportunities.*

06-Dec	<b>Health Care to pursue acquisition opportunities following Luye takeover (Source: The Australian)</b>	<i>Health Care, the Australian hospital operator, is seeking acquisitions in Australia, The Australian reported. As previously reported Archer Capital has sold Health Care to China's Luye Medical Group for AUD 938m (USD 687m). The paper cited Health's chief executive, Steve Atkins, as saying that the company's management team would stay in place following the transaction, which would help the company to expand in the Australia. Atkins noted that the business' primary focus would be to expand in the region and it would continue to seek acquisitions and development opportunities.</i>
06-Dec	<b>Health Care acquired by Luye - report (Source: Australian Financial Review)</b>	<i>China-based Luye Medical Group has acquired Health Care, the Australian hospital operator, the Australian Financial Review's Street Talk reported. According to the unsourced report Luye and Health's owner, Archer Capital, agreed to terms last week. The item noted that Barclays advised Luye. Archer was selling Health Care through Luminis Partners and Morgan Stanley, the paper said.</i>
06-Dec	<b>Eisai to sell all non-core drugs under development - report (translated) (Source: Nihon Keizai Shimbun)</b>	<i>Eisai Co., Ltd., a Japanese pharmaceutical drug maker, will sell all of its drugs under development in non-core areas, the Nihon Keizai Shimbun reported. The company will focus on cancer treatment and drugs for diseases of the central nervous systems, the Japanese newspaper said, without citing sources. The divestments will raise research and development funds, it said.</i>
06-Dec	<b>Amoy Diagnostics files Shenzhen IPO, Citic Securities as IPO sponsor/lead underwriter (Source: CSRC website)</b>	<i>Amoy Diagnostics [Ai De Sheng Wu Yi Yao Ke Ji], a Xiamen, Fujian-based diagnostic products company, has filed its IPO application with the China Securities Regulatory Commission (CSRC); Citic Securities is the IPO sponsor/lead underwriter.</i>
04-Dec	<b>Town Health International Medical to acquire 51%-65% stake in Nanyang Xiangrui Hospital Management Advisory (Source: Stock Exchange Announcement(s))</b>	<i>Town Health International Medical [HKG:3886], a Hong Kong-based healthcare service provider, announced that it has signed an agreement to acquire not less than 51% and up to 65% equity interests in Nanyang Xiangrui Hospital Management Advisory Co. Ltd. The maximum consideration payable by the group is CNY 1,207,142,857 (USD 188.5m).</i>
04-Dec	<b>Nutribiotech plans to list stock on 16 December (translated) (Source: Stock Exchange Announcement (Translated))</b>	<i>Nutribiotech, a South Korean health supplement maker, is seeking to list its shares on 16 December, according to a stock exchange statement. The company has set its IPO price at KRW 21,000 per share. The company will offer 2,080,000 shares through two days' subscription from 7 December. The total IPO size is KRW 43.7bn (USD 37.7m)</i>
04-Dec	<b>Renhe Pharmacy to acquire 60% stake in Beijing Jingwei Yuanhua Pharmaceutical Technology (Source: Stock Exchange Announcement (Translated))</b>	<i>Renhe Pharmacy [Ren He Yao Ye; SZ: 000650], a China-based listed pharmaceutical company, said in a stock exchange announcement tonight that it will acquire a 60% stake in Beijing Jingwei Yuanhua Pharmaceutical Technology [Jing Wei Yuan Hua Yi Yao]. Beijing Jingwei Yuanhua Pharmaceutical Technology is a Beijing-based pharmaceutical retailer.</i>
04-Dec	<b>Sino Health receives Series A financing from Frontline</b>	<i>Frontline BioVentures, a China-based healthcare VC firm, announced today that it has led a Series A round of financing for Sino Health, an invested company of Sinopharm. Frontline BioVentures will provide Sino Health a rich pipeline of innovative products</i>

	<b>BioVentures (Source: Company Press Release(s))</b>	<i>and cutting edge technologies through its network and portfolio companies while also providing seasoned investment expertise.</i>
<b>04-Dec</b>	<b>Mundipharma acquires Merck's glaucoma products portfolio (Source: Company Press Release(s))</b>	<i>Mundipharma Ophthalmology Products Limited today announced an agreement with MSD, known as Merck in the United States and Canada, to acquire MSD's ophthalmology portfolio for the treatment of increased ocular pressure caused by open angle glaucoma or ocular hypertension, in Australia, Canada, Latin America, Middle East, Africa and New Zealand.</i>
<b>03-Dec</b>	<b>Beijing Ruihe Yisheng Technology 49% stake to be sold to Beijing Hanze Century Investment Management for CNY 77.42m (Source: VCCircle)</b>	<i>A 49% stake in Beijing Ruihe Yisheng Technology has been sold to Beijing Hanze Century Investment Management for CNY 77.42m (USD 12.1m) by Beijing Century Real Technology [Shi Ji Rui Er] [SHE:300150], a Chinese-listed railway monitoring software maker, according to a stock exchange announcement that detailed the sales agreement.</i>
<b>03-Dec</b>	<b>New Delhi Centre For Sight files listing document with Sebi (Source: Stock Exchange Announcement (Translated))</b>	<i>New Delhi Centre For Sight, the operator of Indian eye care hospital chain Centre for Sight, has filed its listing document with the capital markets regulator, the Securities and Exchange Board of India (Sebi), VCCircle reported. No sources were disclosed for this. The proposed IPO will include a mix of fresh shares and an offer for sale (OFS) by the company's existing owners and investors.</i>
<b>03-Dec</b>	<b>Pulse Health seeking to raise AUD 40m for acquisition - report (Source: Australian Financial Review)</b>	<i>Pulse Health Limited [ASX:PHG] is seeking to raise AUD 40m (USD 29m) and it intends to put the money towards an acquisition, the Australian Financial Review reported in its Street Talk column. Petra Capital is managing the deal, the Australian newspaper report said, citing unnamed fund manager sources.</i>
<b>03-Dec</b>	<b>Currae Hospitals plans to raise USD 45.1m via equity infusion (Source: The Economic Times)</b>	<i>Currae Hospitals, an Indian healthcare services provider, plans to raise INR 3bn (USD 45.1m) via equity infusion, The Economic Times reported, citing Apoorva Patni, Currae Hospitals' director.</i>
<b>03-Dec</b>	<b>Jiangsu Wuzhong Industrial confirms planning significant assets restructuring, share trading halt expected to last for up to one month (Source: Stock Exchange Announcement (Translated))</b>	<i>Jiangsu Wuzhong Industrial [Wu Zhong Shi Ye; SHA: 600200], a China-based listed company engaged in pharmaceutical and real estate, confirmed in an announcement tonight that its proposed assets purchase will qualify for a significant assets restructuring. Share trading halt in the company will remain on 4 December and is expected to last for up to one month. The company has been in share trading halt since 27 November and it has a market cap of CNY 18.7bn (USD 2.93bn).</i>
<b>03-Dec</b>	<b>Prosetta Biosciences raises USD 31m in Series D (Source: Company Press Release(s))</b>	<i>Prosetta Biosciences, Inc. (the "Company," or "Prosetta"), today announced that it has raised approximately USD 31m in gross proceeds in a private placement. Prosetta is a biotechnology company that is dedicated to the discovery, development and commercialization of innovative and cost-effective human and animal treatments and therapeutics, based on the company's assembly machine-targeted systems.</i>
<b>03-Dec</b>	<b>Vetoquinol and Zenoaq to set up Japan-based JV (Source: Company Press Release(s))</b>	<i>Vetoquinol (Paris:VETO) and Nippon Zenyaku Kogyo Co., Ltd., also operating under the trade name "Zenoaq", announced today the signature of a joint-venture agreement to develop, register and market a range of animal health products in Japan. Headquartered in Koriyama, on Zenoaq's main site, the joint-venture company named Vetoquinol-Zenoaq K.K. will focus on companion animal products, all selected from Vetoquinol's global reference products.</i>

02-Dec	<b>Modern Dental Group to use acquisitions to expand market share and enhance reputation (translated) (Source: Hong Kong Economic Times)</b>	<i>Modern Dental Group, a global dental prosthetic device provider, will use acquisitions as a means to expand its market share and enhance its reputation, the online Hong Kong Economic Times reported. The Chinese language news report, citing CEO Ngai Shing Kin, added that potential takeover targets include trading companies and distributors. The company also plans to invest HKD 240m – HKD 250m to build new manufacturing plants in China, he said.</i>
02-Dec	<b>BTG Pactual sells Rede D'Or Sao Luiz stake to GIC for USD 615m (Source: Company Press Release (Translated))</b>	<i>BTG Pactual, the Brazilian bank has announced in a Portuguese-language release that Grupo BTG Pactual has sold its stake in Rede D'Or Sao Luiz for BRL 2.38bn (USD 615m) to GIC, the Singapore-based sovereign fund.</i>
02-Dec	<b>RG Scientific's owners plan to sell a controlling stakeholding - report (Source: Mint)</b>	<i>The owners of RG Scientific Enterprise, an Indian company which operates the RG Stone chain of chain of tertiary care hospitals, are planning to sell a controlling stake in the company, mint reported, citing two sources in the know. India Equity Partners (IEP), the private equity (PE) firm with nearly 40% stake in RG Scientific, is looking to sell. Meanwhile, Bhim Sen Bansal and family, which own the remaining stake, are planning to dilute an additional 10%-15% stake in RG Scientific.</i>
02-Dec	<b>Narayana Hrudayalaya gets Sebi clearance for IPO (Source: VCCircle)</b>	<i>Narayana Hrudayalaya's IPO application has been cleared by the Securities and Exchange Board of India (Sebi), India's capital markets regulator, VCCircle reported without disclosing sources. The India-based cardiac hospitals chain filed its draft IPO prospectus with Sebi in September.</i>
02-Dec	<b>Hua Xia Healthcare signs MoU for possible acquisition of two companies engaged in management and operation of eight hospitals in China (Source: Stock Exchange Announcement*)</b>	<i>Hua Xia Healthcare (HKG:8143), the Hong Kong-listed healthcare services provider, announced that it has signed a memorandum of understanding for the possible acquisition of two companies engaged in management and operation of eight hospitals in China: The Board announces that on 1 December 2015, the Purchaser, an indirect wholly-owned subsidiary of the Company, as purchaser entered into the non-legally binding MOU with the Vendor, as vendor in relation to the Possible Acquisition.</i>
02-Dec	<b>Vitacare Healthcare forming joint ventures to enter hospital sector (Source: Business World)</b>	<i>Vitacare Healthcare, a Philippines-based healthcare company, is planning to form joint ventures to enter the Philippine hospital sector, reported Business World. The report cited Manuel B. Villar, the owner of the company, who said that the group preferred to form partnerships with doctors. The group recently finalized a partnership with Unimed for the development of Vitacare Unimed Hospital, a 100-bed hospital in the Philippines. The development is valued at PHP 500m (USD 10.6m). A report in Manila Standard Today cited Villar who said that there are plans to open hospitals at 13 other locations. Furthermore, the company prefers the partnership model as opposed to acquiring hospitals outright.</i>
02-Dec	<b>Primary Health Care monitored by buyout groups - report (Source: The Australian)</b>	<i>Buyout groups are said to be closely monitoring Primary Health Care [ASX: PRY], the Australian reported, citing no source. The Dataroom column in the daily reported Primary's market value has fallen by nearly a half since March from AUD 2.8bn (USD 2bn) to AUD 1.6bn. The company was mentioned as a potential target for private equity firms in the past year, but had been considered too expensive.</i>



02-Dec	<b>Health Care bidder Bain Capital brings in JPMorgan to join adviser Citi - report (Source: The Australian)</b>	<i>JPMorgan has joined Citi in advising on Bain Capital's offer for Health Care, the Australian hospital operator, The Australian reported, citing unnamed sources. According to the report in the paper's Dataroom, final bids were due yesterday.</i>
02-Dec	<b>Ascleto closes USD 20m financing led by Goldman Sachs (Source: Company Press Release(s))</b>	<i>Ascleto, a China-based biotechnology company focused on innovative drug development, announced today that Goldman Sachs has completed a USD 20m investment in the company. So far, Ascleto has completed two rounds of financing within the past two months. The first round of USD 35m investment was led by C-Bridge Capital, Tasly Pharmaceutical and Pavilion Capital. "Goldman Sachs is a leading global investment bank.</i>
02-Dec	<b>Innovative Pharmaceutical Biotech issues shares representing 40.98% of issued share capital to Ming Travel International Tourism Investment (Beijing) (Source: Stock Exchange Announcement*)</b>	<i>Innovative Pharmaceutical Biotech (HKG: 399), a gene-testing and pharmaceutical company, announced that it has signed a term sheet for the issue of shares represent approximately 40.98% of its issued share capital to Ming Travel International Tourism Investment (Beijing) Holdings Limited to raise net proceeds of HKD 596.5m (USD 77m): On 29 November 2015, the Company (Innovative Pharmaceutical Biotech) and the Subscriber (Ming Travel International Tourism Investment (Beijing) Holdings Limited) entered into the Term Sheet, pursuant to which the parties have agreed on the indicative terms for the Subscription of 600,000,000 new Shares by the Subscriber at the Subscription Price of HKD 1.00 per Share.</i>
02-Dec	<b>WCCT Global mandates Hana Financial Investment as IPO manager (translated) (Source: Maeil Business)</b>	<i>WCCT Global, the Costa Mesa, California-based contract research organization (CRO), has mandated Hana Financial Investment as an IPO manager, reported Maeil Business.</i>
02-Dec	<b>Chuangmei Pharmaceutical to offer 28 million shares at HKD 7.6 to HKD 8.6 apiece in Hong Kong IPO (Source: Stock Exchange Announcement*)</b>	<i>Chuangmei Pharmaceutical, a Southern China-based pharmaceutical distributor, has announced the details of its plan to list on the mainboard of the Hong Kong stock exchange. A total of 28 million shares, of which 90% being International Offer Shares and 10% Hong Kong Offer Shares, are to be issued in the Share Offer. The share price is to be set at a range from HKD 7.6 to HKD 8.6 per share.</i>
02-Dec	<b>RxMM Health plans to list on ASX by 3Q16 (Source: Company Press Release*)</b>	<i>Boston Securities Group today announced the incorporation of RxMM Health. RxMM Health is establishing operations in Southern California and will install state-of-the-art hydroponic production technology in climate-controlled greenhouses for the cultivation of selected marijuana plant strains in the first half of next year. Climate-controlled greenhouse cultivation eliminates seasonal variability and hydroponic cultivation maximizes quality control and production yield.</i>
01-Dec	<b>MediNet Group files for Hong Kong IPO, Messis Capital is sponsor (Source: Stock Exchange Announcement*)</b>	<i>MediNet Group Limited, a Hong Kong-based corporate medical solutions provider, has filed an application to list on the growth enterprise market of the Hong Kong stock exchange. Messis Capital is the sponsor of the share offer. The company reported revenue of approximately HKD 87m (USD 11.2m) for FY14/15.</i>
01-Dec	<b>Dehaier Medical System attracts Hangzhou Liaison for USD 20m share deal (Source: US Securities</b>	<i>Dehaier Medical System [NASDAQ:DHRM], a Chinese medical devices company, said in a regulatory filing that it has received a non-binding indication of intention from China's Hangzhou Liaison Interactive Information Technology [SHE:002280] for a USD</i>



	<b>and Exchange Commission documents)</b>	20m equity investment. Form 6-K filing On December 1, 2015, the Board of Directors of the Registrant received a nonbinding indication of an intention to invest in the Registrant by Hangzhou Liaison Interactive Information Technology Co. Ltd., a publicly listed company on the Shenzhen Stock Exchange (“Liaison Interactive”). Liaison Interactive proposes to make an equity investment in the Registrant in an aggregate amount of USD 20 million, subscribing for 10 million newly issued common shares of the Registrant for USD 2.00 per share.
01-Dec	<b>SHL Telemedicine terminates transaction with Shanghai Jiuchuan Investment (Source: Company Press Release(s))</b>	SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, announced today that the company has terminated the Merger Agreement with Shanghai Jiuchuan Investment (Group) Co. Ltd. (“Shanghai Jiuchuan”). Shanghai Jiuchuan failed to fulfil the relevant closing conditions stipulated in the Merger Agreement dated as of 24 July 2015 by the extended period until 30 November 2015 granted by SHL in its letter dated 11 November 2015 per Shanghai Jiuchuan’s request.
01-Dec	<b>Hua Xia Healthcare in trading halt pending announcement relating to potential business acquisition of hospitals in China (Source: Stock Exchange Announcement*)</b>	Hua Xia Healthcare (HKG:8143), the Hong Kong-listed healthcare services provider, made the following announcement to the Hong Kong stock exchange: At the request of Hua Xia Healthcare Holdings Limited (the “Company”), trading in the shares of the Company is halted with effect from 9:00 a.m. on Tuesday, 1 December 2015 pending the release of an announcement containing inside information of the Company, which is in relation to a nonlegally binding memorandum of understanding (entered on 1 December 2015) for a potential business acquisition of hospitals in certain areas in the People’s Republic of China.
01-Dec	<b>Baiyang Investment Group in talks to buy Huatai Pharmacy in proposed major asset restructuring (Source: Stock Exchange Announcement (Translated))</b>	Baiyang Investment Group, formerly known as Baiyang Aquatic Group [Bai Yang Gu Fen; SZ: 002696], a China-based listed fishing company, said in a stock exchange announcement on 1 December that it is in talks to buy Jiangxi Huatai Pharmacy [Hua Tai Yao Ye]. Jiangxi Huatai Pharmacy is a privately owned pharmaceutical company.
01-Dec	<b>Chuangmei Pharmaceutical earmarks 15% IPO proceeds for potential acquisitions of pharmaceutical distribution businesses in southern China (translated) (Source: Hong Kong Economic Times)</b>	Chuangmei Pharmaceutical, a Southern China-based pharmaceutical distributor, has earmarked approximately 15% of its IPO proceeds for potential acquisitions of pharmaceutical distribution businesses in southern China, the online Hong Kong Economic Times reported.
01-Dec	<b>Vinapharm gets approval for IPO – report (Source: Vietnam Economic Times)</b>	Vietnam Pharmaceutical Corp (Vinapharm) is going to carry out an initial public offering via an auction following the approval from the country’s prime minister, Vietnam Economic Times reported without citing its source.
01-Dec	<b>BARD1AG to be acquired by Eurogold (Source: Stock Exchange Announcement(s) (Edited))</b>	Eurogold Ltd [ASX: EUG] has entered into binding share sale and purchase agreements under which it has agreed, subject to shareholder approval and the satisfaction of certain other conditions, to acquire all of the issued shares in the capital of BARD1AG

*S.A. (BARD1AG), a Swiss public company limited by shares, according to a notice filed to the Australian Securities Exchange, as follows. Founded in 2011 by Dr Irmgard Irminger-Finger, the head of the Molecular Gynecology and Obstetrics Laboratory at the University Hospital of Geneva (UHG) (and the world's leading BARD1 biology researcher), BARD1AG has pioneered, through the development of certain proprietary intellectual property, a simple blood test for screening and diagnosing lung cancer at early stages of disease progression (the 'BARD1AG Lung Cancer Test').*

---

## DISCLAIMER

---

This Information Package is distributed by Quadria Capital Investment Management ('Quadria Capital') upon the express understanding that no information herein contained is proprietary or has been independently verified. Further, no representation or warranty expressed or implied is made nor is any responsibility of any kind accepted with respect to the completeness or accuracy of any information. Also, no representation or warranty is expressed or implied is made that such information in any respect as of any date or dates after those stated herein with respect to any matter concerning any statement made in this Information Package. Quadria Capital and its Managing Partners, employees, agents and consultants shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from, or for any omissions from the Information Package. All recipients of the Information Package should make their own independent evaluations and should conduct their own investigation and analysis and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers, as they deem necessary.

Where this Information Package summarizes the provisions of any other document, that summary should not be relied upon and the relevant documentation must be referred to for its full effect.



**Abrar Mir**  
Managing Partner

**Quadria Capital Investment Management Pte. Ltd.**  
11A Stanley Street, Singapore 068730  
D +65 6805 9681 M +65 8522 1033  
abrar.mir@quadriacapital.com | www.quadriacapital.com



**Dr. Amit Varma**  
Managing Partner

**Quadria Capital Investment Advisors Pvt. Ltd.**  
D-1, Clarion Collection, Shaheed Jeet Singh Marg, New Delhi – 110 016  
D +91 11 4953 9901 M +91 98 1838 5665  
amit.varma@quadriacapital.com | www.quadriacapital.com

*This publication does not constitute an offer of, or the solicitation of, an offer to buy or subscribe for, any financial instrument or investment, nor shall it (or any part of it or the fact of its distribution) form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract or commitment whatsoever.*